JP5383577B2 - Composition for preventing novel influenza A (H1N1) virus infection comprising ginkgo biloba extract, air filter comprising the composition, and air purifier comprising the filter - Google Patents

Description

  The present invention relates to a composition for preventing new influenza A (H1N1) virus infection containing a ginkgo biloba extract, an air filter containing the composition, and an air purifier equipped with the filter.

  The pandemic influenza A (H1N1) virus, which became a global epidemic from March 2009, is a variant of the influenza virus A subtype H1N1 (English: Influenza A virus subtype H1N1). After that, it was concluded that it was not infected from swine, and the name was abolished. In Korean speech and government, the name of the new flu or new influenza A (H1N1) virus was used. The World Health Organization has raised the H1N1 influenza infectious disease warning level to a pandemic.

  Currently, more than 10,000 people have been infected in Korea based on the announcement on September 16, 2009, 8 are severely hospitalized, and 14 have died from chronic complications or acute complications It is reported.

  Conventionally, drugs used for the treatment of influenza include oseltamivir (trade name: Tamiflu), zanamivir (product life: Relenza), peramivir, Amantadine and the like. Oseltamivir, called Tamiflu, is currently mainly used for the treatment of H1N1 influenza A. Tamiflu is the world's only exclusive avian influenza (AI) treatment. It is an antiviral agent that prevents the enzyme function for proliferating the virus and exerts a therapeutic effect, and has a great therapeutic effect if taken within 48 hours after onset. The main therapeutic effects are a decrease in exacerbation of flu symptoms, a decrease in the occurrence of secondary complications such as bronchitis and pneumonia, and a decrease in fluency incubation period. It is also used as a therapeutic agent for influenza A and B. Zanamivir is also called Zanamivir, and the trade name is Relenza. It acts with a neuraminidase inhibitor and is used to treat influenza A and B.

  However, oseltamivir has a side effect that shows a serious feeling of vomiting, and zanamivir has a high antiviral effect, but has a disadvantage that its bioavailability is low and its excretion in the kidney is fast.

  Most anti-influenza therapeutic agents developed to date show side effects. Therefore, the development of an effective anti-influenza composition for the prevention and treatment of influenza is urgent.

  On the other hand, influenza is usually infected by inhalation of virus-containing fumes that are released into the air by coughing or sneezing. In addition, although it can be transmitted from the excrement, saliva, runny nose, stool and blood of other individuals, most of the transmission can be said to be a droplet infection by inhalation of fumes. Such influenza can be inactivated by surfactants such as sunlight, disinfectant, soap and the like to prevent infection, but has a disadvantage that it is not useful for removing viruses contained in the air.

  Therefore, if such a virus in the air can be removed, influenza infection can be effectively prevented.

  The air filter is a breathable member that filters contaminant particles out of the gas that passes through the filter and purifies the gas that has passed through the filter. Such F filters are used in various places such as home appliances, vehicles, buildings, etc., for example, air purifiers, air conditioners, dryers, vacuum cleaners, humidifiers, dehumidifiers, vehicle air conditioners, center in buildings. Used in air conditioning systems.

  On the other hand, an air cleaner is a device that purifies contaminated air and converts it into fresh air, and a large number of filters are used in one air cleaner. Generally, a pretreatment filter that removes dust with large particles, a deodorization filter that removes harmful substances such as odors, volatile organic compounds, and formaldehyde, a HEPA filter that is a high-performance filter that removes fine dust, and a HEPA filter One or two or more intermediate filters that are installed on the front surface and protect the HEPA filter from dust may be used in one air cleaner.

  The more such filters are used, the better the air cleaning performance. However, in order to increase resistance to the entire air circulation, it is common to use 3 to 5 stage filters as a whole.

  Recently, functional filters that can selectively and more elaborately remove substances harmful to the human body using air purifiers or replace the harmful substances with substances beneficial to the human body have been studied. Examples that have been studied include a high-performance fine substance filter that can filter finer substances for infants, or a filter for exclusive use of the new illness group that can filter harmful substances due to the new symptom group.

  Ginkgo biloba is a typical tree that lives only in Ginkgoales (Ginkgoales), has a pyramid-like body, has few branches on the trunk of a tree like a round pillar, has a height of 30 m, and a diameter of 2. Grows up to 5m. In the case of an old tree, the bark is gray and thick, with vertical cracks, and the wood is corkaceous. Wood is light in color, light and weak and has little economic value. The leaves are fan-like, resembling peafowl leaves, and attach to short, thick young branches. Leather leaves are 8cm long and twice as wide. Two parallel veins extend to each leaf side at the attachment point of the long petiole and branch repeatedly as it goes to the edge of the leaf. Most leaves are divided into two, centering on a central V-shaped cut. The leaves show a light gray-green to yellow-green color in summer, but change to golden in autumn and fall on trees until late autumn. The seeds that have been peeled and dried are called 100 fruits, but they clean the lungs and gastrointestinal tract and are effective for coughing and expectoration. Ginkgoflavone glycoside extracted from ginkgo biloba leaves is used as a blood circulation improving agent.

  Here, in view of the above points, the present inventor is searching for an anti-new influenza A (H1N1) composition, and the ginkgo biloba extract has an excellent anti-new influenza A (H1N1) activity, which is used as an active ingredient. Is used for the prevention of new influenza A (H1N1) virus infection, and by coating the composition on a filter, the new influenza A (H1N1) virus in the air can be effectively removed. And the present invention was completed.

  The object of the present invention is to provide a composition for the prevention of new influenza A (H1N1) virus infection comprising a ginkgo biloba extract.

  Another object of the present invention is to provide an air filter comprising the composition.

  Another object of the present invention is to provide an air purifier including the filter.

  In order to achieve the above object, as an aspect of the present invention, there is provided a composition for preventing new influenza A (H1N1) virus infection comprising a ginkgo biloba extract as an active ingredient.

  According to a preferred embodiment of the present invention, the composition may be used for quasi-drugs.

  According to yet another aspect of the present invention, an air filter comprising the composition is provided.

  According to still another aspect of the present invention, an air purifier including the air filter is provided.

  The composition comprising the ginkgo biloba extract according to the present invention has an excellent anti-new influenza A (H1N1) activity, and is therefore used for the prevention of new influenza A (H1N1) virus infection, and the filter coated with the composition is It can effectively remove the new influenza A (H1N1) virus in the air and is useful for the prevention of new influenza A (H1N1) virus infection.

  Hereinafter, the present invention will be described in detail.

  The present invention provides a composition for preventing novel influenza A (H1N1) virus infection comprising a ginkgo biloba extract as an active ingredient.

  In the context of the present invention, the term “prevention” means any action that, by use of the composition, suppresses new influenza A (H1N1) virus infection or delays its onset.

  The H1N1 influenza virus is the influenza virus type A H1N1 subtype (Influenza A virus subtype H1N1), and is the most common type of influenza that affects humans. Infection and disease may occur in pigs and birds unexpectedly, and specific types include A / PR / 8 (H1N1), A / WSN / 33 (H1N1), A / Bervig-Mission / 1 / 18 (rvH1N1), A / Singapore / 6/86 (H1N1), and the like.

  The new influenza A (H1N1) virus is a virus that caused the 2009 influenza pandemic (A / California / O4 / 09, A / California / 7/2009, etc.).

  In the present invention, the new influenza A (H1N1) virus causes flu, cold, sore throat, bronchitis, and pneumonia.

  In the present invention, Ginkgo biloba may be purchased and used commercially, or collected or cultivated from nature.

  In the present invention, ginkgo may use parts such as leaves, fruits, bark, and roots, and preferably leaves, but is not limited thereto.

  In the present invention, the ginkgo biloba extract may be extracted by any method that can be extracted from a simple extraction method to a fat-soluble component, and is pulverized and extracted for easy extraction. Extraction with a solvent, which is obtained by filtration and concentration.

  Examples of the extraction solvent include water, ethanol, methanol, butanol, n-hexane, n-heptane, and DMSO. These two or more solvents may be mixed and used as an extraction solvent. However, a person skilled in the art can appropriately select from known methods according to the amount of raw material to be extracted, the extraction method, and the like. The extraction time and temperature can also be appropriately selected from known methods by those skilled in the art in consideration of extraction efficiency, extraction solvent, and the like. A preferable extraction time is 10 minutes to 1 hour, and a preferable extraction temperature is 40 to 100 ° C.

  Moreover, after extracting the extract extracted by the said extraction method with well-known filtration methods, such as vacuum filtration, it can concentrate by distillation etc. Such extraction, filtration, and concentration methods are widely known in the art, and thus those skilled in the art can appropriately select them to produce ginkgo biloba extract.

  According to another embodiment of the present invention, the composition for preventing influenza A (H1N1) virus infection of the present invention can be used as a non-pharmaceutical product.

  That is, the composition of the present invention may be added to quasi-drugs for the purpose of preventing new influenza A (H1N1) virus infection. When the composition of the present invention is used as a quasi-drug additive, the composition may be added as it is, or may be used together with other quasi-drugs or quasi-drug components, or may be used as appropriate by a conventional method. Good. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use.

  Preferably, the quasi-drug composition may be used in the manufacture of a filter coating agent, hand washing, rinsing, disinfecting and cleaning agent, shower foam, wet tissue, soap, humidifier filler, mask, or fragrance. .

  Moreover, this invention provides the air filter containing the composition for prevention of the said novel influenza A (H1N1) virus infection.

  In the present invention, the term “air filter” refers to removing microorganisms and dust in the air, preventing inflow of dangerous substances or contaminants such as microorganisms and dust from the outside, and preventing secondary contamination by the filter. Means a filter for. Therefore, the air filter according to the present invention may be used as an air filter for automobiles, an air filter for household appliances, an air filter for an air conditioner, an air filter for a gas mask, an air filter for an air purifier, an air filter for a clean loam, It is preferably used for an air filter for an air purifier.

  Furthermore, the present invention provides a method for producing an air filter comprising the above-described composition for preventing influenza A (H1N1) virus infection. Hereinafter, the above-described composition for preventing influenza A (H1N1) virus infection is provided. The manufacturing method of the air filter containing is demonstrated.

A method for producing an air filter comprising a composition for preventing infection of the novel influenza A (H1N1) virus of the present invention,
(A) producing a composition for preventing new influenza A (H1N1) virus infection;
(B) coating the filter substrate with the composition for preventing infection of the novel influenza A (H1N1) virus;
(C) drying the coated filter;
In step (b),
Immersing a roller in the composition for preventing influenza A (H1N1) virus infection, and then applying the solution to the filter substrate using the immersed roller;
Immersing a roller containing the filter base material in the composition for preventing influenza A (H1N1) virus infection;
It is performed by any one or more steps selected from the group consisting of spraying the composition for preventing infection with the new influenza A (H1N1) virus onto the filter substrate.

  As the filter substrate, metal, plastic, non-woven fabric, film or the like may be used. As the air filter for the air purifier, a highly porous nonwoven fabric is preferably used, but is not limited thereto.

  Examples of the plastic material include polypropylene, polyethylene, polyurethane, acrylic, PVC, and polystyrene. However, the plastic material is not limited thereto, and is preferably polypropylene.

  Non-woven fabric means a sheet-like cloth using fibers or the like that are appropriately arranged with fibers or the like, or an adhesive or its own fusing force. Depending on the base material, a paper-based non-woven fabric, a fiber-based non-woven fabric, etc. is there. Nonwoven fabric materials include rayon, tencel, or polypropylene, but are not limited thereto, and any material known in the art can be used as an ordinary nonwoven fabric material. Polypropylene is preferable.

  The filter substrate of the present invention is a weaving form in which a filament yarn produced by melting and spinning a plastic resin at a temperature near the melting point is woven, or a web of fibers (lattice entangled) without weaving the fibers. Can be made into a non-woven fiber filter to which it is bonded, or it can be made into a porous foam filter by adding a foaming agent.

  In order to manufacture an air filter, first, a composition for preventing infection with a new influenza A (H1N1) virus is manufactured. The novel influenza A (H1N1) virus infection-preventing composition may be preferably dissolved or diluted with a certain solvent and used in the production of an air filter in the form of a solution. Here, as the solvent, water, ethanol, methanol, butanol, or n-hexane, n-heptane, DMSO, or a mixed solvent thereof may be used.

  The filter substrate is coated with the composition for preventing infection with the new influenza A (H1N1) virus. The coating method includes a method in which a roller provided with a water-absorbing member such as a sponge is immersed in the composition, and then the roller is rolled on a filter substrate and dried to coat the filter base. There are a method in which a material is directly immersed in the composition and dried to coat, a method in which the composition is sprayed on the filter substrate and dried to coat.

  The coating process for producing the filter of the present invention can be applied to an already produced filter substrate, and can also be applied at the stage of fiber form before weaving the filter. In the case of the fiber form, the filter weaving fiber is first subjected to a coating process in which the composition of the present invention is immersed or sprayed, and after the coating process, the filter substrate is woven.

  When drying the filter coated with the composition of the present invention by dipping or spraying, the filter may be dried at room temperature or hot air, and any drying method known in the art can be used without limitation. By drying, the composition of the present invention is well adsorbed on the filter, and the filter can have antibacterial effect for a long time.

  In addition to the composition of the present invention, the filter of the present invention is an existing antibacterial substance, deodorant (eg, flavonoid, phytoncide, wood vinegar, plant extract, cyclodextrin, metal ion, titanium dioxide) or a dust collecting filter. These components may be separately applied together or separately for each component, and the order of application is not particularly limited.

  The present invention also provides an air purifier including the air filter.

  Referring to an air purifier as an example in which the air filter of the present invention is used, as described above, a number of filters are used in the air purifier, but the prevention of new influenza A (H1N1) virus infection according to the present invention. The air filter including the composition for use may be used as a functional filter, and may be used as any filter included in other air purifiers.

  The air purifier to which the air filter of the present invention is applied is not limited, and examples thereof include an air purifier in a home or office room, a filter for automobile / indoor purifying, and the like. Ordinary components included in other air purifiers may be included. Preferably, the air purifier of the present invention is formed by disposing the air filter of the present invention between an air inlet and an outlet.

  The present invention also provides an air cleaning method using the air cleaner.

  Hereinafter, the present invention will be described in more detail with reference to examples and experimental examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[Production Example 1: Production of ginkgo biloba extract]
The ginkgo biloba used in this production example was used after collecting the leaf part, and then drying to obtain the extract of the present invention efficiently, and then pulverizing it into a powder. 5 g of water was added to 1 kg of ginkgo biloba, extracted by boiling in a water bath at 80 ° C. for 12 hours, filtered through filter paper, and concentrated to obtain a ginkgo biloba extract.

[Production Example 2: Production of air filter according to the present invention coated with ginkgo biloba extract]
A polypropylene filter substrate was spray-coated with a solution obtained by diluting the ginkgo extract prepared in Preparation Example 1 with water, and dried at 140 ° C. for 4 minutes to produce a filter.

[Experimental Example 1: Measurement of killing activity of influenza A (H1N1) virus by Ginkgo biloba extract]
The influenza virus killing activity of the ginkgo biloba extract obtained in Production Example 1 of the present invention was measured as follows.

  As an influenza virus, the WHO standard strain influenza virus H1N1 (A / California / O4 /) was introduced as the new influenza A (H1N1) virus declared the 2009 pandemic (World Health Organization, declared on June 11, 2009). 09) and A / PR / 8 (H1N1) and A / WSN (H1N1) were used as other H1N1 type viruses already known as H1N1 types. As a sample, the ginkgo biloba extract obtained in Production Example 1 was used. A more specific experimental method is as follows.

First, MDCK (Mardine Darvine Canine Kidney) cell line was inoculated at a concentration of 1.5 × 10 ⁶ cells / ml and then in a 6-well plate for 24 hours in an incubator at 37 ° C. and 5% CO ₂ concentration. Cultured. In addition, the ginkgo biloba extract was diluted with water at 100 mg / ml (1 ×), and this was diluted 10 times to prepare a sample. 90 μl of each of the prepared samples was placed in a 96-well plate, treated with 10 μl of influenza virus and reacted for 10 minutes, and then diluted 10-fold with PBS. Thereafter, the MDCK cell line, which became a full dish in the culture dish, was infected with 1 ml of the diluted solution for 1 hour. On the other hand, a control group of “infection + non-administration” (a group of cells that were infected with influenza virus and were not administered with Ginkgo biloba extract) was reacted under the same conditions, then inoculated into the MDCK cell line and cultured.

  Thereafter, the medium was removed, and 2 × MEM medium containing 2 × agarose and 10 μg / ml trypsin was mixed at a weight ratio of 1: 1, and then 2 ml each was poured onto each plate containing the MDCK cell line. The MDCK cell line was cultured in an incubator at 37 ° C. for 2 days, and then fixed with 1 ml of 4% paraformaldehyde and washed with water to remove agarose. Thereafter, the number of plaques was measured by staining with crystal violet, and the number was calculated in terms of plaque forming units (pfu / ml). The results are shown in Tables 1-3.

Formula 1
Virus inhibition rate (%) = (1-ginkgo biloba extract treatment group / control group) × 100
Table 1
The titer of new influenza A (H1N1) (A / California / O4 / 09) after each sample treatment

Table 2
Influenza A / WSN / 33 (H1N1) titer after each sample treatment

Table 3
Influenza A / PR / 8 (H1N1) titer after each sample treatment

  According to the results of Tables 1 to 3, when the Ginkgo biloba extract is treated as compared with the control group, the virus is significantly reduced. Therefore, the Ginkgo biloba extract according to the present invention has excellent anti-influenza virus killing activity. I understand.

[Experimental Example 2: Measurement of anti-influenza virus killing activity of air filter according to the present invention]
The killing activity of influenza A (H1N1) virus of the air filter treated with the ginkgo biloba extract obtained in Production Example 2 of the present invention was measured as follows.

  As an influenza virus, the WHO standard strain influenza virus H1N1 (A / California / O4 /) was introduced as the new influenza A (H1N1) virus declared the 2009 pandemic (World Health Organization, declared on June 11, 2009). 09) and A / PR / 8/34 (H1N1) and A / WSN / 33 (H1N1) were used as other H1N1 type viruses already known as H1N1 types. As a sample, the air filter obtained in Production Example 2 was used. As a control group, an air filter which was not treated with any extract was used. A more specific experimental method is as follows.

  After collecting the filter medium to 2 × 2 cm, apply a certain amount of virus solution to the filter and absorb and react with the filter medium for 10 minutes, and then put a medium (1 ml) on the absorbed filter. Shake for a minute to wash out the virus. This was diluted to prepare a sample. 90 μl of each of the prepared samples was placed in a 96-well plate and treated with 10 μl of influenza virus. After reacting for 10 minutes, the solution was diluted 10-fold with PBS. Thereafter, the MDCK cell line, which became a full dish in the culture dish, was infected with 1 ml of the diluted solution for 1 hour. On the other hand, a control group of “infection + non-administration” (a cell group to which no extract was administered after infection with influenza virus) was reacted under the same conditions, then inoculated into an MDCK cell line and cultured.

  Thereafter, the medium was removed, 2 × MEM medium containing 2 × agarose and 10 μg / ml trypsin was mixed at a weight ratio of 1: 1, and then 2 ml each was poured onto a plate containing the MDCK cell line. The MDCK cell line was cultured in an incubator at 37 ° C. for 2 days, and then fixed with 1 ml of 4% paraformaldehyde and washed with water to remove agarose. Thereafter, the number of plaques was measured by staining with crystal violet, and the number was calculated in terms of plaque forming units (pfu / ml). The results are shown in Tables 4-6.

Table 4
The titer of new influenza A (H1N1) (A / California / O4 / 09) after each sample treatment

Table 5
Influenza A / WSN / 33 (H1N1) titer after each sample treatment

Table 6
Influenza A / PR / 8 (H1N1) titer after each sample treatment

  From the results of Tables 4 to 6, it can be seen that the Ginkgo biloba extract-treated air filter according to the present invention has excellent influenza virus killing activity.

Claims (2)

A composition for preventing infection with a new influenza A (H1N1) virus, comprising a ginkgo biloba extract as an active ingredient,
The new influenza A (H1N1) virus, Ri A / California / 04/09 der,
The extract is extracted with water,
The Ginkgo, new influenza A (H1N1) prophylactic composition of viral infections characterized by site Der Rukoto leaf.   The composition for preventing infection of new influenza A (H1N1) virus according to claim 1, wherein the disease caused by infection with the new influenza A (H1N1) virus is flu, cold, sore throat, bronchitis, pneumonia object.